Your browser doesn't support javascript.
Remdesivir for patients with COVID-19.
Wu, Peter E; Morris, Andrew M.
  • Wu PE; Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont. peter.wu@uhn.ca.
  • Morris AM; Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont.
CMAJ ; 193(4): E125, 2021 01 25.
Article in English | MEDLINE | ID: covidwho-1013234

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: CMAJ Journal subject: Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: CMAJ Journal subject: Medicine Year: 2021 Document Type: Article